Simple chemical tweak redirects mRNA vaccines from liver to lungs and spleen
This week brought major advances in making mRNA vaccines smarter about where they go in the bodyβplus promising results for everything from Alzheimer's to parasitic diseases.
π― One atom swap redirects mRNA vaccines to different organs
Researchers replaced a single nitrogen atom with sulfur in the widely-used vaccine lipid ALC-0315, completely changing where mRNA vaccines go in the bodyβfrom liver to lungs
The modified lipid (S-ALC-0315) mixed with the original at a 1:2 ratio created vaccines that specifically targeted the spleen instead
Spleen-targeting vaccines generated stronger anti-tumor immune responses and produced significant anti-cancer effects in two different tumor models while maintaining safety
Why it matters: This atomic-level modification offers a simple way to reprogram existing approved vaccine components for different diseases without starting from scratch with new safety testing.
Key Findings
π§ CRISPR gene editing clears Alzheimer's plaques in mouse brains
Scientists used lipid nanoparticles to deliver CRISPR tools that boost Mt3 protein production in brain support cells (astrocytes)
The enhanced Mt3 expression significantly increased astrocytes' ability to engulf and clear amyloid-beta plaques
Direct brain injection of the CRISPR system led to a marked reduction in plaque accumulation in Alzheimer's disease mice
π¦ mRNA vaccines show promise against neglected parasitic diseases
Researchers outlined how mRNA vaccine technology could tackle parasitic infections that affect vulnerable populations worldwide
The adaptable platform can target complex parasite life cycles and effectively modulate immune responses
Key challenges include cold-chain storage requirements, manufacturing scale-up, and community acceptance in resource-limited settings
π Virus-like particle mRNA vaccines outperform standard COVID shots
mRNA vaccines encoding virus-like particles (mRNA-VLPs) generated stronger neutralizing antibody responses across multiple COVID variants compared to conventional spike protein vaccines
In non-human primates, elevated antibody levels lasted at least six months
Even low doses of mRNA-VLP vaccines provided complete protection in hamsters, matching the performance of high-dose standard vaccines
π« Targeted lung delivery enhances cancer immunotherapy
Mannose-modified lipid nanoparticles delivered both silencing RNA and immune-stimulating mRNA specifically to lung macrophages
The combination therapy reprogrammed tumor-promoting immune cells into cancer-fighting ones
When combined with checkpoint inhibitors, the treatment significantly boosted anti-tumor responses in lung cancer and lung metastasis models
π©Έ mRNA produces clotting factor for hemophilia treatment
Lipid nanoparticles carrying mRNA for the MG1113 antibody (which targets a clotting inhibitor) enabled sustained antibody production in mice and rabbits
The mRNA approach provided longer-lasting effects and more efficient plasma protein suppression compared to direct antibody injection
This factor-independent strategy could offer prolonged treatment with simplified manufacturing
π¬ Getting COVID and flu shots together doesn't weaken immune response
A randomized trial of 335 people found no reduction in COVID vaccine effectiveness when given simultaneously with flu shots
Antibody levels against the original virus strain and BA.4/5 variant were nearly identical between simultaneous and sequential vaccination groups
Post-vaccination antibody titers were 4,357 vs 4,492 for simultaneous vs sequential groups (no significant difference)
Implications
These studies show mRNA technology is rapidly expanding beyond COVID vaccines into precision medicine. The ability to redirect vaccines to specific organs and cell types, combined with growing applications in cancer, genetic diseases, and neglected infections, suggests we're entering an era where mRNA can be programmed like software to target exactly where therapeutic action is needed.
Studies in this issue
Primary sources used for this newsletter.
- Changing mRNA delivery targets by replacing nitrogen with sulfur in charged lipidsmain storyAdvanced materials (Deerfield Beach, Fla.)2025-12-12PMID 41386688
- mRNA Vaccines and Treatments for Parasitic Infections: A Complete Overviewkey findingJournal of nanobiotechnology2025-12-13PMID 41390653
- Immune response and protection from an mRNA vaccine using a virus-like spike protein against COVID-19key findingNPJ vaccines2025-12-13PMID 41390346
- Boosting a Protective Protein in Brain Support Cells May Improve Clearing of Alzheimer's Amyloid in Micekey findingAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025-12-12PMID 41387343
- Immune response to mRNA COVID-19 vaccine given at the same time or after flu shots: a randomized trialkey findingVaccine2025-12-11PMID 41380398
- Lung immune cell-targeted RNA delivery using special lipid particles may improve lung cancer immunotherapykey findingJournal of controlled release : official journal of the Controlled Release Society2025-12-10PMID 41371503
- Using mRNA to produce MG1113 antibody inside the body as a possible treatment for hemophiliakey findingJournal of controlled release : official journal of the Controlled Release Society2025-12-09PMID 41365435
Continue reading
All mRNA Technology issuesGet the next mRNA Technology issue
Seven papers, once a week. Free.